MK-2461 is a novel ATP-competitive multitargeted kinase inhibitor that preferentially inhibits the activated c-Met receptor. MK-2461 is also a potent inhibitor of Ron, Flt1, Flt 3, PDGFRβ, and Mer receptors. Recent studies show that MK-2461 siginifciantly suppresses tumor growth of GTL-16 xenografts in mice and MK-2461 treatments effectively inhibit the growth of NIH3T3 tumors harboring c-Met single nucleotide mutants T3936C and T3997C.
MK-2461 is a potent inhibitor of c-Met, Ron, Flt1/3, PDGFRβ, Mer and FGFR1/2/3 with IC50 of 2.5 nM, 7 nM, 10 nM/22 nM, 22 nM, 24 nM and 65 nM/39 nM/50 nM, respectively.
mk-2461 is a potent inhibitor of met, flt1, flt 3, ron, pdgfrβ, and mer with ic50 of 2.5 nm, 10 nm, 22 nm, 7 nm, and 24 nm, respectively.c-met, also named as hepatocyte growth factor receptor (hgfr) is a receptor tyrosine kinase that is essential for embryonic development and would healing. in many tumor cells, this molecular is overexpressed or mutated and was found to play important roles in tumor cell proliferation, survival, invasion, metastasis and angiogenesis.in a murine xenograft model of c-met-dependent gastric cancer, oral administration of mk-2461 at a dosge of 100 mg/kg twice daily effectively inhibited c-met signaling and tumor growth 1. consistently, mk-2461 inhibited the tumor growth which was formed by s.c. injection of mouse nih-3t3 cells expressing oncogenic c-met mutants 1. these evidence support the preclinical development of mk-2461 for cancer therapy.
mk-2461treatment blocked hepatocyte growth factor/c-met- dependent mitogenesis, migration, cell scatter, and tubulogenesis 1.
1. pan bs, chan gk, chenard m, et al. mk-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-met receptor. cancer research. 2010;70(4):1524-1533.
